Seminar – From IND to BLA: Advancing the Next Generation of Cell & Gene Therapies
Cell and gene therapy development is advancing rapidly, but the path from IND to BLA remains complex. Success requires well-coordinated CMC, manufacturing, and regulatory strategies across each stage of development.
Watch the on-demand sessions from ProBio Korea CGT Symposium 2026 for expert insights into lentiviral vectors, mRNA-tLNP platforms for in vivo CAR-T, IIT-to-IND translation, and regulatory planning.
Watch the on-demand sessions from ProBio Korea CGT Symposium 2026 for expert insights into lentiviral vectors, mRNA-tLNP platforms for in vivo CAR-T, IIT-to-IND translation, and regulatory planning.
Speaker
Topic
Jennifer Ju
Head of Korea Business Development, ProBio
[Presented in Korean]
Navigating the Successful CAR-T Roadmap from IND to BLA: Essential Lentiviral Vector CMC StrategiesHead of Korea Business Development, ProBio
00:00
00:00
Hyung Cheol Kim, Ph.D.
Executive Vice President, Head of R&D Center, Curocell
[Presented in Korean]
Securing Commercial Grade LVV Supply to Achieve Market Approval for CAR-T TherapiesExecutive Vice President, Head of R&D Center, Curocell
[Presented in Korean]
00:00
00:00
Kevin Chen, Ph.D.
Head of mRNA Business Dept., ProBio
mRNA - tLNP for in vivo CAR-T: Challenge and Solution
Head of mRNA Business Dept., ProBio
00:00
00:00
Yuefeng Li, Ph.D.
Sr. Scientist, LVV Process Development & Vector R&D, ProBio
From Vector Backbone to Process: Systematic Design and Development Strategies for In Vivo CAR-T Lentiviral Vectors
Sr. Scientist, LVV Process Development & Vector R&D, ProBio
00:00
00:00
Xingwen Li, Ph.D.
Manager, CGT Technology Center, ProBio
Bridging China IITs to IND: Translational CMC Strategies for CGT Therapies through an End-to-End IIT Ecosystem
Manager, CGT Technology Center, ProBio
00:00
00:00
Tina Yu
Sr. Director, Regulatory Affairs Dept., ProBio
Exploring Regulatory Strategies to Accelerate CGT Drug Development
Sr. Director, Regulatory Affairs Dept, ProBio
00:00
00:00
